Androgenetic alopecia is a genetic disorder caused by an overreaction to androgens. This condition affects up to 50% of males and females and is characterized by progressive loss of terminal hair o...
FDA Approves BeiGene’s Brukinsa for CLL/SLL BeiGene's Brukinsa (zanubrutinib) for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) has been approved by the US Food and Drug Administration. CLL is a common type of leukemia, accounting for approximately 25% of all new cases each year. SLL is...
Find More
AbbVie Secures Fourth FDA Approval for Vraylar AbbVie has received its fourth FDA approval for Vraylar, adding major depressive disorder (MDD) adjunctive therapy to a list that includes schizophrenia and manic and depressive episodes in bipolar disorder. According to AbbVie, the approval makes Vraylar (cariprazi...
Find More
Amgen Inc. Agrees to Purchase Dublin-based Horizon Therapeutics Plc. for €24.7 Billion Amgen Inc. has agreed to buy Dublin-based Horizon Therapeutics Plc. for €24.7 billion ($26 billion), in a deal that could face further delays or a breakdown in negotiations. Following Sanofi's withdrawal from the race, c...
Find More
Myotonic dystrophy (DM), known as "the most variable of all diseases found in medicine," is a multi-systemic genetic disorder that is the most common form of adult-onset muscular dystrophy. myotonic dystrophy is the only type of muscular dystrophy that affects cognition and brain function, in addition to the heart,...
Find More
Bioinformatics is one of the healthcare industry's most spotlighted and trending topics today. The Bioinformatics market is evolving rapidly and reaching new heights with each passing day, leading to new insights and information into molecular sequence and genomics. Moreover, it makes handling and analyzing genomic...
Find More
Gene therapy is an experimental technique that introduces functional genes into a patient’s body to counteract or replace defective ones, thereby curing disease without using pharmaceuticals, radiotherapy, or surgery. Genetic defects that are difficult to treat with drugs or antibodies can be treated with therapy w...
Find More
Amgen Reports Promising Mid-stage Results for its Olpasiran Candidate Amgen has reported encouraging mid-stage results for its olpasiran candidate for lowering lipoprotein(a) - a risk factor for atherosclerotic cardiovascular disease - and now plans to move forward with a phase III program as soon as possi...
Find More
Hemophilia A treatment scenario before the launch of HEMLIBRA Despite the ups and downs throughout history, the management of hemophilia A patients substantially improved over the past 40 years. The groundbreaking discovery of cryoprecipitate in 1964 marked the beginning of the modern progression of hemophilia t...
Find More
Actinium Announces Positive Top-line Results from Pivotal Phase III SIERRA Trial of Iomab-B Actinium Pharma is on track to submit its targeted radiotherapy for AML patients requiring a bone marrow transplant in the United States, boosted by top-line data from a pivotal trial. The SIERRA trial of Iomab-B, an anti...
Find More
The first biosimilar was made available to patients in the United States six years ago in 2021. Thes.....
Find More-Featured.png)
Neuromyelitis Optica Spectrum Disorder (NMOSD), also known as Devic disease, is a chronic disorder o.....
Find More
A rare neurological disorder characterized by progressive weakness and impaired sensory function in .....
Find More
Transthyretin Amyloidosis (ATTR) is a progressive build-up of abnormal deposits of amyloid protein i.....
Find More
The pharma industry has played a crucial role in fighting against the pandemic situation by supplyin.....
Find More
Hospital-acquired bacterial pneumonia (HABP) is the most common type of health-care-associated infec.....
Find More-Agonist.png "Toll-like Receptors Agonist")
The American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.
